Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study
Related Articles
Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order
Development of effective treatments for amyotrophic lateral sclerosis (ALS) has been hampered by disease heterogeneity, a limited understanding of underlying pathophysiology, and methodologic design challenges.…
Cannabis use in Parkinson’s disease—A nationwide online survey study
Abstract Objectives The aim of this study was to investigate the frequency of use, attitudes toward, and experiences with cannabis and cannabis-related products among people…
Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis
There are few treatments shown to slow disability progression in progressive multiple sclerosis (PMS). One challenge has been efficiently testing the pipeline of candidate therapies…
Modelling the cascade of biomarker changes in GRN-related frontotemporal dementia
Objective Progranulin-related frontotemporal dementia (FTD-GRN) is a fast progressive disease. Modelling the cascade of multimodal biomarker changes aids in understanding the aetiology of this disease…
Amyotrophic Lateral Sclerosis-Frontotemporal Dementia: Shared and Divergent Neural Correlates Across the Clinical Spectrum
Background and Objectives A significant overlap between amyotrophic lateral sclerosis (ALS) and behavioral variant of frontotemporal dementia (bvFTD) has been observed at clinical, genetic, and…
English
العربية
简体中文
Nederlands
Français
Deutsch
Italiano
Português
Русский
Español
Responses